E1224
Phase 2Small molecule
E1224 is one of 8 small molecule programs targeting Chagas disease. It is currently in Phase 2.
1
Indications
3
Total Trials
0
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Chagas Disease
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Benznidazole
CCorestemchemon, Inc.
Approved
Noxafil
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
Selenium
SSWOG Cancer Research Network
Phase 3
Fexinidazole
SanofiPhase 2
LXE408
NovartisPhase 2
E1224
DDrugs for Neglected Diseases
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for E1224. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- DDrugs for Neglected Diseases